Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there ...

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.

Lilly ‌was granted a voucher for its obesity pill, ‍orforglipron, in November as part of a deal with ⁠the Trump ...

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...

Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...

At this year’s American College of Allergy, Asthma & Immunology Scientific Meeting, Anne K. Ellis, MD, MSc, FACAAI, received ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

Regeneron's new antibody drug, Lynozyfic, shows promise in eradicating residual multiple myeloma without the need for bone marrow transplants, according to a small mid-stage trial. The treatment ...